Biomarker-Guided Oncology Practice in Non–Small Cell Lung Cancer: Utilization Patterns, Turnaround Time, and Sector-Associated Access Barriers
Keywords:
Precision oncology, NSCLC, biomarker utilization, implementation barriers, molecular diagnostics, healthcare disparities.Abstract
Background: Biomarker-guided therapy has become standard in advanced non-small cell lung cancer (NSCLC), yet real-world implementation varies across healthcare sectors. Objective: To evaluate biomarker utilization, turnaround time, and structural access barriers among oncology clinicians and to assess whether public-sector practice is associated with higher implementation burden. Methods: A cross-sectional survey of 125 oncology professionals assessed utilization of five NSCLC biomarkers, turnaround time for single-gene and next-generation sequencing testing, and the frequency and severity of access barriers. A composite Barrier Burden Score was calculated, and sector-based comparisons were performed using ANOVA. Results: EGFR testing in at least 50% of eligible patients was reported by 64.8%, PD-L1 by 68.8%, and KRAS by 53.6%. NGS turnaround exceeded 21 days in 57.6% of respondents. Patient affordability (61.6%) and absence of reimbursement (52.0%) were the most frequently reported barriers. Public-sector clinicians demonstrated significantly higher Barrier Burden Scores compared with private-sector clinicians (17.96 ± 5.82 vs. 12.23 ± 5.23; mean difference 5.73; p = 0.003). High biomarker utilization, defined as at least 4 of 5 markers tested in at least 50% of eligible patients, was observed in 40.8%. Conclusion: Biomarker utilization was moderate and sectorally variable, with higher cumulative barrier burden associated with public-sector practice. Financial and infrastructural constraints correspond with implementation disparities and warrant targeted system-level interventions.
References
1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
2. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29:iv192-iv237.
3. Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV NSCLC without driver alterations: ASCO guideline. J Clin Oncol. 2021;39:1040-1091.
4. Aggarwal A, Lewison G, Idir S, et al. The state of lung cancer research. Lancet Oncol. 2017;18:e464-e473.
5. Ginsburg O, et al. Cancer control in LMICs. CA Cancer J Clin. 2017;67:3-20.
6. Rolfo C, et al. Molecular testing in lung cancer. J Thorac Oncol. 2021;16:164-176.
7. Malone ER, et al. Molecular profiling for precision oncology. Nat Rev Clin Oncol. 2020;17:403-418.
8. Merker JD, et al. Somatic variant classification guidelines. J Mol Diagn. 2018;20:17-37.
9. Lim C, et al. Real-world molecular testing delays. JCO Precis Oncol. 2020;4:123-132.
10. Luchini C, et al. Precision oncology barriers. ESMO Open. 2020;5:e000853.
11. Pennell NA, et al. Barriers to biomarker testing. JCO Oncol Pract. 2019;15:e101-e111.
12. Vail PJ, et al. Molecular disparities. JCO Glob Oncol. 2020;6:141-150.
13. Phillips KA, et al. Economic challenges in precision medicine. Health Aff. 2018;37:108-115.
14. von Elm E, et al. STROBE statement. PLoS Med. 2007;4:e296.
15. Bossuyt PM, et al. Reporting diagnostic studies. BMJ. 2015;351:h5527.
16. Proctor EK, et al. Implementation outcomes framework. Adm Policy Ment Health. 2011;38:65-76.
17. Damschroder LJ, et al. Consolidated framework for implementation research. Implement Sci. 2009;4:50.
18. Sterne JA, et al. Multiple imputation. BMJ. 2009;338:b2393.
19. Naing L, et al. Sample size determination. Malays J Med Sci. 2006;13:84-86.
20. Leighl NB, et al. Global EGFR testing patterns. J Thorac Oncol. 2019;14:150-160.
21. Hirsch FR, et al. PD-L1 testing in NSCLC. Lancet. 2017;389:299-311.
22. Sabari JK, et al. KRAS testing and targeted therapy evolution. Clin Cancer Res. 2018;24:137-145.
23. Lim C, et al. Impact of molecular turnaround time. JCO Precis Oncol. 2020;4:123-132.
24. Zafar SY, et al. Financial toxicity in oncology. Oncologist. 2013;18:381-390.
25. Mailankody S, et al. Cost of targeted cancer therapy. JAMA Oncol. 2017;3:1080-1082.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Tooba Aftab, Faryal Ilyas (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright is retained by the Author(s). Published in JPMHR under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Unrestricted reuse is permitted with proper attribution to the author(s) and source.
